Studies: Pharmaceutical:
Fenretinide Lym-X-Sorb® in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma:
This phase I trial is studying the side effects and best dose of fenretinide Lym-X-Sorb® in treating patients with recurrent or resistant solid tumors or lymphoma. NCT00589381
Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas # 08-C-0030:
A Phase I Study of Fenretinide (4-HPR, NSC 374551) formulated in Lym-X-Sorb® (LXS) as an oral powder will be evaluated in patient with recurrent or resistant neuroblastoma (NEW APPROACHES TO NEUROBLASTOMA THERAPY (NANT) CONSORTIUM, 7/8/05).
NCI - Maurer/CHLA - Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma NCT00295919 New Approaches to Neuroblastoma:
RATIONALE: Drugs used in chemotherapy, such as fenretinide LXS, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.